FANJ
ITCI

Financial Architects (New Jersey)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Financial Architects (New Jersey)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-5,000
Closed -$172K – 940
2019
Q4 		$172K Buy
+5,000
New +$60K 0.04% 260

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Architects (New Jersey)'s ITCI Position: Q1 2020 in Review

Financial Architects (New Jersey) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2020, closing a stake of 5,000 shares — an estimated $172K sold.

Financial Architects (New Jersey) first reported a position in ITCI in Q4 2019 and held it in 1 quarter. The position peaked at $172K in Q4 2019. 139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Financial Architects (New Jersey) reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2020 after selling out during the quarter.
  • Financial Architects (New Jersey) sold 5,000 Intra-Cellular Therapies Inc. shares in Q1 2020, an estimated $172K.
  • Financial Architects (New Jersey) first reported a position in Intra-Cellular Therapies Inc. in Q4 2019 and held it in 1 quarter.
  • Financial Architects (New Jersey)'s Intra-Cellular Therapies Inc. position peaked at $172K in Q4 2019.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Financial Architects (New Jersey)'s 13F filing for Q1 2020, filed 7 May 2020.